Our objective was to define the frequency of these autoantibodies in a large cohort of carefully characterized patients with PTLD meeting a research case definition and to determine the clinical implications of these tests. RF and ACPA were tested as indicated clinically and abstracted by chart review. This evidence concerns the gene PRTN3 and post-transplant lymphoproliferative disease.